SNOA Sonoma Pharmaceuticals, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1367083 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.7%
TTM net income YoY48.4%
TTM EPS YoY55.2%
Revenue 3-yr CAGR24.7%
Net income 3-yr CAGR—
Margins
Gross margin39.2%
Operating margin-3.3%
Net margin-7.6%
FCF margin-11.9%
EBITDA margin-2.8%
Returns
ROE-34.5%
ROA-11.6%
ROIC (approx.)-44.6%
Asset turnover1.52x
Leverage & solvency
Liabilities / assets61.3%
Debt / equity0.00x
Current ratio3.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.49x
Accruals ratio5.6%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $19.53M | $14.29M |
| Cost of revenue | $12.11M | $8.82M |
| Gross profit | $7.42M | $5.46M |
| R&D expense | $2.27M | $1.81M |
| SG&A expense | $7.61M | $7.36M |
| Operating income | -$2.46M | -$3.71M |
| Pretax income | -$3.42M | -$2.91M |
| Income tax | -$244,000 | $550,000 |
| Net income | -$3.17M | -$3.46M |
| EBITDA | -$2.32M | -$3.57M |
| EPS (basic) | -1.89 | -2.79 |
| EPS (diluted) | -1.89 | -2.79 |
| Weighted avg. shares (diluted) | 1.68M | 1.24M |
| Balance sheet | ||
| Cash & equivalents | $2.40M | $5.37M |
| Receivables | $2.53M | $2.23M |
| Inventory | $3.65M | $2.92M |
| Current assets | $12.10M | $12.65M |
| PP&E, net | $310,000 | $225,000 |
| Total assets | $13.96M | $13.69M |
| Current liabilities | $4.83M | $4.10M |
| Short-term debt | $222,000 | $220,000 |
| Total liabilities | $10.87M | $9.28M |
| Shareholders' equity | $3.10M | $4.41M |
| Shares outstanding | 1.80M | 1.63M |
| Cash flow statement | ||
| Operating cash flow | -$3.93M | -$88,000 |
| Capital expenditure | $192,000 | $80,000 |
| Free cash flow | -$4.12M | -$168,000 |
| Investing cash flow | -$192,000 | -$80,000 |
| Financing cash flow | $477,000 | $3.03M |
| Depreciation & amortization | $139,000 | $138,000 |
| Stock-based compensation | $255,000 | $224,000 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.